BIOQUAL Inc. reports recurring financial results and governance updates as an OTC Pink/Pink Limited public company. Its announcements center on quarterly and annual revenue, income or loss before taxes, net income or loss, earnings per common share, and weighted average shares outstanding.
Company news also documents board and senior leadership changes, including retirements and appointments connected to corporate oversight and BIOQUAL's contract research program.
BIOQUAL, Inc. (OTC Pink: BIOQ) reported its unaudited financial results for the third quarter ended February 28, 2023. The company generated revenue of $46.6 million for the nine months, a slight decline from $47.8 million in the previous year. In the third quarter alone, revenue was $14.1 million, compared to $17.1 million in the same period of 2022. The income before tax decreased to $2.17 million from $4.77 million year-over-year, while net income showed a decrease to $1.54 million from $3.37 million. Basic earnings per share (EPS) fell to $1.72 from $3.77, with diluted EPS also declining to $1.72 from $3.77. The company faces ongoing challenges including reliance on government contracts and the need for sufficient animal models.
BIOQUAL, Inc. (OTC-Pink:BIOQ) reported its unaudited second quarter results for fiscal year 2023. For the six months ended November 30, 2022, the company generated revenues of $32.49 million, an increase from $30.67 million in the same period last year. Net income rose to $2.68 million, up from $2.52 million in 2021. Basic earnings per share were $2.99, compared to $2.81 in the prior year. The results reflect the company’s solid performance and increasing demand for its animal models in scientific research. Forward-looking statements highlight potential risks related to government contracts and market demand.
BIOQUAL, Inc. (OTC-Pink: BIOQ) reported its fiscal year 2023 first quarter results ending August 31. Revenue increased to $15.81 million, up from $15.47 million in the same quarter last year. Income before tax was $1.96 million, marginally up from $1.95 million. Net income showed a slight increase to $1.38 million, compared to $1.38 million previously. Basic and diluted earnings per share improved to $1.55, reflecting a positive trend in earnings. For complete details, visit www.bioqual.com.
BIOQUAL, Inc. has announced the promotion of Charles (Chris) C. Kirk, Jr. to Chief Financial Officer. With over 25 years of experience in finance and accounting, Mr. Kirk previously served as Director of Finance and Accounting at BIOQUAL. He will lead the company’s Accounting/Finance team and join the executive leadership. The press release also highlights potential risks and uncertainties affecting the company’s operations, such as contract extensions, demand for animal models, and financial management.
BIOQUAL has declared a $1.00 per share dividend for shareholders of record on October 6, 2022, payable on October 27, 2022. This marks the twenty-first dividend issued by the company.
While the announcement reflects the company's ongoing commitment to returning value to shareholders, the press release also includes forward-looking statements that highlight risks related to securing government contracts, managing costs, and the availability of resources.
BIOQUAL, Inc. (OTC-Pink:BIOQ) reported a revenue increase to $66.15 million in 2022, up from $57.68 million in 2021. However, net income fell to $5.26 million, down from $6.33 million, reflecting a 16.9% decline. The basic and diluted earnings per share decreased to $5.88 from $7.08. While the company maintains steady operations, concerns regarding contract performance and potential financing challenges may affect future growth.
BIOQUAL, Inc. announces the retirement of CFO Dave Newcomer, effective June 3, 2022, after serving since 1994. He will remain to aid in the transition to his successor, Charles (Chris) C. Kirk, Jr., who has over 25 years of financial experience. Newcomer will also join the Board of Directors following his retirement to utilize his company knowledge. This leadership transition emphasizes continuity as BIOQUAL addresses market challenges, including government contracts and demand for animal models in research.
BIOQUAL, Inc. has announced the appointment of Hanne Andersen Elyard, PhD, as its first Chief Scientific Officer, a role aimed at enhancing the company’s contract research efforts in infectious diseases. With over 17 years at BIOQUAL, Dr. Elyard is expected to lead the expansion of preclinical testing models and laboratory analysis. CEO Mark Lewis expressed confidence in her leadership capabilities, noting her extensive experience in microbiology and contract research. The PR also includes forward-looking statements about potential risks and uncertainties affecting the company's operations.
BIOQUAL, Inc. (OTC-Pink: BIOQ) reported significant financial results for the nine months ended February 28, 2022, with revenue of $47.81 million, a 16.7% increase compared to $41.07 million in the same period of 2021. Net income for the nine months was $3.37 million, with basic earnings per share at $3.77 and diluted earnings per share also at $3.77. In the three months ended February 28, 2022, the company achieved revenue of $17.13 million, up from $12.58 million in 2021, and net income reached $856,588, demonstrating profitability growth in a competitive market.
BIOQUAL, Inc. (OTC-Pink: BIOQ) reported its financial results for the six months and three months ended November 30, 2021. Revenue for the six months was $30.67 million, an increase from $28.49 million in the previous year. The company recorded a net income of $2.52 million, compared to $3.23 million year-over-year. Earnings per share were $2.81 basic and diluted. The results reflect a solid performance with a 9% revenue growth, but a decline in net income indicates potential cost management challenges going forward.